Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

CLEAR Trial: Lenvatinib plus Pembrolizumab in Advanced RCC

December 13th 2023

Experts highlight key clinical updates from the CLEAR trial presented at the 2023 IKCS: North America congress, assessing lenvatinib plus pembrolizumab in patients with advanced RCC.

The Evolution of Advanced Renal Cell Carcinoma

December 13th 2023

Brian Rini, MD, and Hans Hammers, MD, PhD, discuss the evolution of management for advanced renal cell carcinoma (RCC), noting the role of biomarkers and its use in practice.

Novel Therapies for Advanced RCC: LITESPARK-005 and Treatment Sequencing

December 12th 2023

Leading oncologists discuss advanced treatment options for patients with progressing renal cell carcinoma (RCC), focusing on the promising results from LITESPARK-005 and treatment sequencing strategies.

Navigating Toxicity Discussions With Patients With Renal Cell Carcinoma

December 12th 2023

Expert insight into how to discuss and manage treatment-related toxicities with cancer patients and their families, emphasizing the importance of early communication and vigilance.

State of Science Summit- Genitourinary Cancer: Chaired by Petros Grivas, MD, PhD, and Evan Y. Yu, MD

December 12th 2023

State of Science Summit- Genitourinary Cancer: Chaired by Petros Grivas, MD, PhD, and Evan Y. Yu, MD

Bladder Cancer: Treatment Options and Managing Adverse Effects

December 7th 2023

Comprehensive insights on treatment considerations and managing immunotherapy-related adverse effects for patients with bladder cancer.

Monitoring Patients With NMIBC

December 7th 2023

The panel discusses strategies for monitoring patients with non–muscle invasive bladder cancer and the potential role of biomarkers.

Sequencing and Second-Line Therapy in RCC: Patient Scenario

December 5th 2023

Expert oncologists discuss the challenges and considerations in choosing second-line therapy for a patient with metastatic renal cell carcinoma (RCC) in a case-based context.

Dr Maksimovic on a Novel Preclinical Model of Bone Metastasis in ccRCC

December 5th 2023

Stefan Maksimovic, MD, discusses the preclinical investigation of innovative tissue engineering with optical windows, state-of-the-art fluorescence reporter technology, and intravital multiphoton microscopy in mouse models with clear cell renal cell carcinoma.

TKI and Immunotherapy Combo Efforts in RCC Remain of Interest as Treatment Arsenal Evolves

December 4th 2023

Final outcomes from the phase 1b/2 Study 111/KEYNOTE-146 trial, evaluating treatment with lenvatinib and pembrolizumab in patients with advanced renal cell carcinoma, has sparked interest in the use of this combination.

Dr Karam on Key Kidney Cancer Takeaways From the 2023 IKCS

December 1st 2023

Jose A. Karam, MD, FACS, discusses key takeaways from the 2023 International Kidney Cancer Symposium.

Dr Jonasch on the Evolution of Belzutifan in Cancer Care

December 1st 2023

Eric Jonasch, MD, discusses the evolution of belzutifan in cancer care, highlighting the agent’s potential for the treatment of patients with renal cell carcinoma.

Dr Vaishampayan on the Rationale For the SWOG-1931/PROBE Trial in Advanced RCC

December 1st 2023

Ulka Nitin Vaishampayan, MBBS, discusses the rationale for conducting the phase 3 SWOG 1931 trial in patients with advanced renal cell carcinoma.

State of Science Summit: Prostate/Bladder Cancer - Chaired by Edwin M. Posadas, MD

November 30th 2023

State of Science Summit: Prostate/Bladder Cancer - Chaired by Edwin M. Posadas, MD

Treatment Considerations and Role of Trimodal Therapy in Bladder Cancer

November 30th 2023

Expert perspectives on treatment options available for patients with bladder cancer and the role of trimodal therapy.

Overview of Non–Muscle Invasive Bladder Cancer (NMIBC)

November 30th 2023

A panel of experts on bladder cancer provide an overview of the stratification, natural history, and treatment of bladder cancer.

Dr Hurwitz on Ongoing Investigations of the Use of CAR T-Cell Therapy in Solid Tumors

November 30th 2023

Michael Hurwitz, MD, PhD, discusses the ongoing investigation into the use of CAR T-cell therapies in patients with solid tumors, such as kidney cancers.

Dr Desai on the Implications of the CONTACT-03 Trial in RCC

November 28th 2023

Arpita Desai, MD, discusses the impact that the findings from the phase 3 CONTACT-03 trial had in patients with metastatic renal cell carcinoma.

Dr Qin on Upcoming Areas of Interest in RCC Research

November 28th 2023

Qian (Janie) Qin, MD, discusses upcoming areas of interest in the renal cell carcinoma armamentarium.

Key Decision Factors in Selecting Frontline Therapy for Metastatic RCC

November 28th 2023

Renowned oncologists discuss critical factors influencing their decisions for frontline therapy in metastatic renal cell carcinoma (RCC), including risk assessment, sites of metastasis, performance status, and treatment goals.